Welcome to our dedicated page for Creative Med Technology Hldgs SEC filings (Ticker: CELZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) provides direct access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. These documents offer detailed insight into Creative Medical’s governance, financing activities, and progress across its regenerative medicine, regenerative immunotherapy, and AI-enabled biodefense platforms.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on CELZ’s business description, risk factors, research and development focus, and financial statements. These filings typically discuss the company’s key programs, including AlloStem/CELZ-201 (olastrocel), ImmCelz, and iPScelz, as well as clinical initiatives in degenerative disc disease, chronic lower back pain, Type 1 diabetes, and biodefense-related indications.
Current reports on Form 8-K highlight material events such as warrant exercise inducement agreements, unregistered sales of equity securities, and compensation decisions for senior executives. For example, recent 8-K filings describe inducement warrant transactions used to raise working capital and general corporate funds, along with related advisory arrangements.
Proxy statements on Schedule 14A (DEF 14A) detail matters submitted to stockholders, including the election of directors, advisory votes on executive compensation, auditor ratification, and special meeting proposals to approve the exercise of inducement warrants in accordance with Nasdaq Listing Rule 5635(d). These documents provide visibility into CELZ’s corporate governance structure and stockholder voting items.
Through this page, users can also monitor registration statements and any available Form 4 insider transaction reports, where applicable, to understand how securities are being issued and how insiders transact in the company’s stock. Stock Titan enhances this information with AI-powered summaries that explain the key points of lengthy filings, highlight important changes, and help readers interpret complex disclosures in 10-Ks, 10-Qs, 8-Ks, and proxy materials.
Together, these SEC filings form an authoritative record of Creative Medical Technology Holdings’ regulatory, financial, and corporate activities, supporting deeper analysis of CELZ as a clinical-stage biotechnology company.
Creative Medical Technology Holdings, Inc. reported cash and short-term investments of $6,544,120 and total assets of $7,105,228 at June 30, 2025, with positive working capital of approximately $6,355,063 and stockholders' equity of $6,827,584. The company remains unprofitable, recording a six-month net loss of $2,871,400 versus $2,599,272 a year earlier.
Commercial revenue was minimal: $0 for the quarter and $3,000 for the six months, down from $8,000 a year ago. Operating loss for the six months was $2,923,998. Research and development expense for the six months totaled $1,244,565 while selling, general and administrative expense was $1,619,914. Basic net loss per share for six months was $(1.26) on a weighted average of 2,282,290 shares.
The company strengthened liquidity through warrant exercises and related financings, generating approximately $3.7 million of net proceeds during the period and reporting 4,147,478 warrants outstanding at June 30, 2025. Clinical programs show material progress: an independent Data Safety Monitoring Board completed a safety review and recommended continuation of the CELZ-201 ADAPT trial after initial cohorts, and the company completed dosing of the second cohort (20 patients total) in Q2 2025.